P
Pieris Pharmaceuticals
PIRS
16.990
USD
0.48
(2.91%)
مغلق
حجم التداول
575
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
22,444,080
الأخبار
العنوان: Pieris Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.